Top Section/Ad
Top Section/Ad
Most recent
US drug maker's stake in Haleon set to fall to 24%
Risk appetite is back and more deals coming, though one bad IPO would damage confidence in the recovery
More companies are getting ratings to woo bond investors
Europe's biggest IPO of the year so far gains traction with investors
After the listings in February delivered, Galderma adds fuel to the European IPO recovery
Long delayed listing of Nestlé's former skincare division is finally underway
LivaNova and MicroStrategy ride US tech convertible wave as maturity wall pushes issuers to refinance
Bankers hopeful more supply will follow, but no pipeline forthcoming
The strong market conditions are tempting cash rich issuers
Three borrowers head to euros to fund M&A activity
US corporate bond market jumping with deals despite inflation shock on Tuesday
Share sale achieved a tight discount of 2.3%
IPO volumes on the London Stock Exchange fell to levels not seen since the global financial crisis levels in 2023
More articles/Ad
More articles/Ad
More articles
-
MDs in Germany join after 17 senior hires in the US over 16 months
-
The Italian maker of luxury gym equipment rose over 7% in trading on Friday following the Saudi entry into the stock
-
Euro primary continues pumping out trades with JDE Peet's and Covivio lining up
-
Swiss pharma company navigates a difficult market to pay a negative to zero new issue premium
-
Strong name recognition helps Swiss pharma company achieve size at a tight price
-
Novartis spin off looks to build on jubilant reception it had last month in Swissies